• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·600721.SS
Share

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd Stocks

CN¥ 6.75Last Updated 13.07.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

CN¥ 385.91M

CN¥ 6.75
Key Takeaways

Risk factor

Meaningful price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd conducts its operations across a diverse range of business sectors. Its core activities encompass pharmaceutical research and development, clinical studies, and the field of biomedicine, alongside investments in commercial properties and various other ventures. This enterprise, officially renamed Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021, previously operated as Xinjiang Baihuacun Co., Ltd. Established in 1959, the company maintains its headquarters in Urumqi, China.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.07.2026 14:37

Shares of L’Oréal’s small-cap partner have surged. It will go private

13.07.2026 13:45

SK Hynix Shares Have Their Worst Day Ever After a Record-Breaking U.S. Debut. Is It Time to Buy?

13.07.2026 13:09

Meta shut down its new AI photo-generation feature less than a week after its launch

13.07.2026 11:45

Wall Street's New Leaders: Who Will Succeed Buffett and Dalio?

13.07.2026 11:04

Oil prices approached $80 per barrel amid renewed tensions between the U.S. and Iran

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026